Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs

[1]  J. Bousquet,et al.  Correction to: MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence , 2019, Clinical and Translational Allergy.

[2]  J. Bousquet,et al.  Mobile health tools for the management of chronic respiratory diseases , 2019, Allergy.

[3]  A. Sheikh,et al.  2019 ARIA Care pathways for allergen immunotherapy , 2019, Allergy.

[4]  S. Vieths,et al.  Understanding differences in allergen immunotherapy products and practices in North America and Europe. , 2019, The Journal of allergy and clinical immunology.

[5]  C. Bachert,et al.  Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma , 2019, The Journal of allergy and clinical immunology.

[6]  G. Scadding.  Legends of Allergy/ Immunology: Alfred William (Bill) Frankland , 2018, Allergy.

[7]  L. Klimek,et al.  Recent developments and highlights in allergen immunotherapy , 2018, Allergy.

[8]  Rosalind W. Picard,et al.  MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence , 2018, Clinical and Translational Allergy.

[9]  Daniel Laune,et al.  POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project , 2018, Clinical and Translational Allergy.

[10]  A. Sheikh,et al.  Treatment of allergic rhinitis using mobile technology with real‐world data: The MASK observational pilot study , 2018, Allergy.

[11]  S. Durham,et al.  UK Immunotherapy Study: Reanalysis by a combined symptom and medication score. , 2018, The Journal of allergy and clinical immunology.

[12]  Boleslaw Samolinski,et al.  Electronic Clinical Decision Support System for allergic rhinitis management: MASK e‐CDSS , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[13]  S. Durham,et al.  EAACI Position paper on the standardization of nasal allergen challenges , 2018, Allergy.

[14]  C. Bachert,et al.  Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial , 2018, Allergy.

[15]  O. Pfaar,et al.  Placebo effects in allergen immunotherapy: an experts’ opinion , 2018, Allergo Journal International.

[16]  O. Pfaar,et al.  Clinical trials in allergen immunotherapy: current concepts and future needs , 2018, Allergy.

[17]  A. Sheikh,et al.  EAACI guidelines on allergen immunotherapy: Executive statement , 2018, Allergy.

[18]  A. Sheikh,et al.  EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis , 2018, Allergy.

[19]  A. Sheikh,et al.  Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project , 2018, Allergy.

[20]  A. Sheikh,et al.  Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products , 2018, Allergy.

[21]  P. Demoly,et al.  Perspectives in allergen immunotherapy: 2017 and beyond , 2018, Allergy.

[22]  E. Valovirta,et al.  Results from the 5‐year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy , 2017, The Journal of allergy and clinical immunology.

[23]  D. Ryan,et al.  Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement , 2017, Allergy.

[24]  P Demoly,et al.  Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper , 2017, Allergy.

[25]  T. Zuberbier,et al.  Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an EAACI Position Paper , 2017, Allergy.

[26]  S. Durham,et al.  Novel approaches and perspectives in allergen immunotherapy , 2017, Allergy.

[27]  J. Bousquet,et al.  Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report , 2017, Clinical and Translational Allergy.

[28]  A. Sheikh,et al.  Allergen immunotherapy for allergic asthma: A systematic review and meta‐analysis , 2017, Allergy.

[29]  A. Sheikh,et al.  Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta‐analysis , 2017, Allergy.

[30]  N. Bansback,et al.  The burden of nonadherence among adults with asthma: a role for shared decision‐making , 2017, Allergy.

[31]  A. Plaia,et al.  Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review , 2017, Allergy.

[32]  R. Gerth van Wijk,et al.  Use of the Control of Allergic Rhinitis and Asthma Test (CARATkids) in children and adolescents: Validation in Dutch , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[33]  A. Sheikh,et al.  Allergen immunotherapy for the prevention of allergy: A systematic review and meta‐analysis , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[34]  L. Delgado,et al.  Conjunctival allergen provocation test : guidelines for daily practice , 2017, Allergy.

[35]  R. Van Ree,et al.  International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. , 2016, The Journal of allergy and clinical immunology.

[36]  T. Casale,et al.  Sublingual grass and ragweed immunotherapy: Clinical considerations-a PRACTALL consensus report. , 2016, The Journal of allergy and clinical immunology.

[37]  B. García,et al.  Optimal duration of allergen immunotherapy in children with dust mite respiratory allergy , 2015, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[38]  R. Gerth van Wijk,et al.  The minimal clinically important difference of the control of allergic rhinitis and asthma test (CARAT): cross-cultural validation and relation with pollen counts , 2015, npj Primary Care Respiratory Medicine.

[39]  E. Vicaut,et al.  The minimally important difference in the Rhinoconjunctivitis Total Symptom Score in grass‐pollen‐induced allergic rhinoconjunctivitis , 2014, Allergy.

[40]  J. Bousquet,et al.  Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. , 2014, Allergy.

[41]  O. Pfaar,et al.  The placebo effect in allergen-specific immunotherapy trials , 2013, Clinical and Translational Allergy.

[42]  P. Enck,et al.  Placebo effects in children: a review , 2013, Pediatric Research.

[43]  R. Gerth van Wijk,et al.  Perspectives on allergen‐specific immunotherapy in childhood: An EAACI position statement , 2012, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[44]  P. Howarth,et al.  How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA‐GA2LEN statement , 2011, Allergy.

[45]  J. Bousquet,et al.  Unmet needs in severe chronic upper airway disease (SCUAD). , 2009, The Journal of allergy and clinical immunology.

[46]  J. Bousquet,et al.  Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis. , 2009, The Journal of allergy and clinical immunology.

[47]  J Bousquet,et al.  Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce , 2007, Allergy.

[48]  G. Guyatt,et al.  How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure , 2006, Health and quality of life outcomes.

[49]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[50]  Ferrié,et al.  Development and validation of the Mini Rhinoconjunctivitis Quality of Life Questionnaire , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[51]  W. Jonas,et al.  Toward a research agenda on placebo. , 2000, Advances in mind-body medicine.

[52]  Doris Ma Fat,et al.  WHO Library Cataloguing-in-Publication Data , 2001 .

[53]  E. Juniper,et al.  Measuring quality of life in children with rhinoconjunctivitis. , 1998, The Journal of allergy and clinical immunology.

[54]  P. Gøtzsche.  Is there logic in the placebo? , 1994, The Lancet.

[55]  G. Guyatt,et al.  Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. , 1994, The Journal of allergy and clinical immunology.

[56]  G. Guyatt,et al.  Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[57]  L. Noon.  Prophylactic inoculation against hay fever. , 1911, International archives of allergy and applied immunology.